article · BMC Infectious Diseases

Incidence of dynamic seroconversion in subjects received the first dose of the SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa, Democratic Republic of Congo: prospective cohort study

2025Open accessUniversité de Kinshasa (UNIKIN)

Abstract

The vaccines used had conferred significant immunity on subjects upon receipt of the first dose. This immunity appears to be greater when using the mRNA vaccine than when using the inactivated vaccine.

Research topics

SARS-CoV-2 and COVID-19 Research
COVID-19 Clinical Research Studies
Vaccine Coverage and Hesitancy

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1186/s12879-025-10754-4

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.